BCL2L1 and lymphoma: High levels of Mcl-1 and Bcl-XL have been reported to be a mechanism of both de novo [54] and acquired [55] resistance to ABT-199 in lymphoma cell lines, which is overcome by the addition of mTOR inhibitors [55], and possibly with acadesine.